In 1993, a 54-year-old woman was diagnosed with early-stage breast adenocarcinoma and treated with doxorubicin and cyclophosphamide followed by tamoxifen. Nine years later, the patient presented for integrative treatment, with liver metastases. Carcinoembryonic antigen was significantly elevated. The patient was started on a heavily fractionated, multiple-agent chemotherapy regimen; however, she underwent significant adverse effects and the treatment was suspended. She then started on intravenous nutrition along with specific nutritional supplements. Two months later, a similar chemotherapeutic regimen was started in association with her existing nutritional protocol. One month later, the carcinoembryonic antigen began to rise, and a positron emission tomography scan was ordered that revealed the persistence of multiple and extensive liver metastases as well as possible skeletal metastases. The patient was started on an oral bisphosphonate and referred to interventional radiology for consultation on radioembolization with yttrium-90. After being accepted for treatment, the patient underwent a right hepatic lobe angiogram and radioembolization. Within 2 weeks, she realized significant improvements in her clinical and laboratory status; chemotherapy was discontinued. She later underwent radioembolization to her left lobe. Thirteen months after the yttrium-90 treatment, the patient remains on an integrative program with radiographically and clinically stable disease.
In December of 1993, a 44-year-old premenopausal woman (S.M.) noticed a lump in the upper outer quadrant of her left breast and presented to her primary care physician. Her sister had died of breast cancer at age 47. A biopsy was performed on December 24, 1993, demonstrating a grade I, infiltrating ductal carcinoma. Fifteen days later, a modified radical mastectomy was performed at the Mayo Clinic in Rochester. Final pathology indicated a 2.0 × 1.0 × 1.2 cm, T 2 N 0 M 0 , grade IV/IV, estrogen receptor-borderlinepositive and progesterone receptor-positive breast adenocarcinoma. Subsequently, the patient received classic National Surgical Adjuvant Breast and Bowel Project high-dose doxorubicin/cyclophosphamide schedule for 4 cycles, followed by 5 years of tamoxifen dosed at 10 mg, twice daily.
As indicated by medical records and patient interviews, in January 1999, S.M. presented to medical oncology for her 5-year checkup. She was found to be free of disease and was counseled to stop the tamoxifen after 5 years, in April 1999. Between that date and March 2002, S.M. began raloxifene, 60 mg daily. A physician's note in the medical chart dated March 2002 remarks that S.M. had complaints of worsening epigastric pain and increasing fatigue. No costovertebral angle tenderness, breast masses, discharge, or organomegaly were observed. Axillary nodes were negative, the abdomen was soft and nontender, and bowel sounds were present in 4 quadrants. No diagnostic imaging was performed.
On December 17, 2002, S.M. presented again with still worsening abdominal pain, this time with a palpable local firmness, along with esophageal reflux and nausea and was subsequently admitted to hospital. A computed tomography (CT) scan performed that day demonstrated multiple varying-sized mixed attenuation hepatic masses, consistent with metastatic deposits; a total body bone scan was negative for suggestion of metastatic disease but did show degenerative change at the right L 5 segment. This prompted a full metastatic workup. Hepatic biospy confirmed the presence of metastatic adenocarcinoma. Subsequent immunohistochemical staining was negative for progesterone and estrogen receptors but had a staining intensity of 3+, indicative of gene amplification of HER2/neu. Pertinent laboratory data from this time period are shown in Table 1 .
After receiving the diagnosis of metastatic breast cancer, S.M., a registered nurse, began to seek other options. She presented to the Aidan Clinic, an integrative treatment clinic for people with cancer in Tempe, Arizona (no longer active), on January 13, 2003, for a consultation regarding a treatment plan. At this first presentation, integrative and conventional treatments were discussed. Conventional options included singleor combination-agent chemotherapy such as a taxane, gemcitabine, vinorelbine, or perhaps a fluoropyrimidine such as capecitabine. S.M.'s liver function status at that time would have probably prevented her participation in any clinical trials other than phase I studies. After being offered similar treatment advice from her medical oncologist, S.M. subsequently declined conventional treatment. A protocol was designed for her unique situation at the integrative clinic. Before treatment, however, a new CT scan was ordered. Significant findings on January 15, 2003, were innumerable, variably sized heterogenous, low-density lesions scattered throughout both lobes of the liver, consistent with diffuse metastatic disease. The largest lesions were in the medial segment of the left lobe of the liver inferiorly and the right lobe of the liver inferiorly, each measuring approximately 7 cm in maximal diameter. The rest of the abdominal and pelvic scans were unremarkable. No thoracic evaluation was performed.
S.M. then began her comprehensive treatment plan, which included heavily fractionated chemotherapy, nutritional and medicinal supplements, diet and lifestyle counseling, and a preparatory protocol for potential experimental immunotherapy. The chemotherapy was administered per heavy fractionation and potentiated with insulin, based on the principles, but not protocols, of the practice of insulin potentiation therapy. 1 The specific cytotoxics used during this time were gemcitabine, docetaxel, doxorubicin, cyclophosphamide, carboplatin, and vinblastine. Four treatments were given in the first 7 days and then continued once weekly. However, after the first scheduled weekly treatment, S.M. had a significant adverse reaction that called for discontinuation of the chemotherapy. Laboratory studies at that time (January 30, 2003) are shown in Table 1 .
Shortly thereafter, S.M. was started on a high-dose intravenous vitamin C protocol and an oral supplement protocol consisting mainly of the following: epigallocatechin gallate, melatonin, curcuminoids, "green-foods" formula, indole 3-carbinol, oral vitamin C, proteolytic enzymes away from meals, omega-3 fish oils, a multivitamin, and a calcium supplement. A CT of the abdomen was also performed. Other than a decrease in size of the previously 7 cm lesion to 6 cm in the right lobe of the liver, there were no interval changes. Chest CT at this time was negative for findings of metastatic disease; the pelvis remained normal as well. S.M. was continued on her protocol through March 18, 2003, when fractionated, insulinpotentiated chemotherapy was resumed. However, for this similar series, lyophilized doxorubicin was substituted for standard doxorubicin, twice weekly. Laboratory parameters at this time are shown in Table 1 .
S.M. tolerated the chemotherapeutic treatments well, and in early April 2003, she was restaged with positron emission tomography (PET) imaging. Findings were as follows: the survey was positive, showing multiple and extensive liver metastases in both the right and left lobes, with at least 2 bone metastases suggested in the lateral aspect of a right midthoracic rib and in the right half of the third lumbar vertebra. Laboratory results in April 2003, after the PET scan, are shown in Table 1 .
S.M. began an oral bisphosphonate and continued her oral supplements and vitamin C IV therapy (given on nonchemotherapy days) along with the fractionated, potentiated chemotherapy.* Over the course of the next month, S.M. performed fairly well in the clinic but had significant changes in her laboratory parameters, specifically, a consistent elevation of her carcinoembryonic antigen (CEA). A referral was made to an interventional radiologist, employing SIR-Spheres, a form of yttrium-90 radioembolization used concomitantly with chemotherapy for patients with metastatic liver disease. 2 S.M. presented to Good Samaritan Regional Medical Center in Phoenix, Arizona, for yttrium-90 radioembolization evaluation for her metastatic liver disease. Her contrast-enhanced CT and PET scans demonstrated extensive bilobar liver-predominant metastatic breast cancer (Figure 1 ).
She underwent hepatic angiography to evaluate the liver anatomy and tumor distribution ( Figure 2) . A test injection of Technetium 99 macroagreggated albumin (MAA), which is 10 to 90 µm in size, was performed through an angiographic catheter in the proper hepatic artery. The femoral artery was percutaneously sealed, and the patient was transferred to the nuclear medicine department for planar imaging of the chest and abdomen to determine the liver-shunt ratio (Figure 3) .
A Technetium 99 MAA hepatic arterial injection simulates a therapeutic yttrium-90 radioembolization procedure. Technetium emits a low-energy, 90-kev photon that is easy to image with standard nuclear medicine equipment. The Technetium 99 MAA particles injected in the liver artery become trapped at the precapillary level because of their physical size. Planar and single-photon emission computed tomography imaging of the chest and abdomen are performed. Any beads that pass through the hepatic intratumoral arteriovenous shunts will become trapped within the pulmonary capillary bed. The shunt ratio through the liver is calculated. If the shunt ratio is less than 20%, the patient qualifies for high-dose yttrium-90 therapy. The lungs can tolerate only 16.5 mCi of radiation before being exposed to potentially fatal radiation pneumonitis. The dose of yttrium-90 is ordered, and the patient is treated within 2 weeks. S.M. underwent a right hepatic lobe angiogram and SIR-Spheres radioembolization a week after the diagnostic angiogram. She was pretreated with 32 mg of ondansetron and 10 mg of dexamethasone given intravenously. The SIR-Spheres were administered through a 5 French angiographic catheter placed via the right common femoral artery in interventional radiology. The procedure took less than an hour, and the patient was sent home the same day.
SIR-Spheres is a commercially available product manufactured by Sirtex, Ltd. Yttrium-90 is attached to spheres that are 30 µm in size. Yttrium-90 emits a very high-energy 940-kev photon with a 64-hour half-life but travels only 2.5 mm in tissue. A typical dose administered in the hepatic artery contains about 20 to 60 million spheres. The radioactive spheres become trapped at the precapillary level in the tumor where they exert their localized radiation effect causing coagulative necrosis and cell death. Because of 
A B
neovascularity, there is a hyperaccumulation of beads in the tumor relatively sparing the normal liver tissue. During radioembolization, S.M. continued the integrative protocol including fractionated, insulinpotentiated chemotherapy and both her intravenous vitamin C and nutritional supplement protocol. Slight modifications were made to accommodate for events ensuing within the hepatic parenchyma, including detoxification and nutritional hepatic support.
Within 2 weeks of the initial SIR-Spheres administration, S.M. realized a significant improvement in her laboratory status as shown in Table 1 . This was concomitant with an overall improvement in her clinical status as well. Chemotherapy was discontinued, and S.M. continued to do well. One month after the right lobe radioembolization, S.M. returned for a left lobe treatment. She underwent a left hepatic angiogram with SIR-Spheres radioembolization as an outpatient and was discharged the same day. No complications occurred. It was then recommended that S.M. return to her home state and continue her treatment with a local physician. She was discharged from the Aidan Clinic with a protocol for intravenous vitamin C, nutritional supplementation, and ultra-low-dose immunotherapy with the pharmaceutical cytokines interleukin-2 and granulocyte macrophage-colonystimulating factor. Her laboratory parameters continued to stabilize, and her CEA continued to decrease. Upon discharge, her CEA was 85.4, the lowest since the start of her treatment at the integrative clinic. While back in her home area, her oncologist still followed CEA, but the local laboratory used a different assay method than that employed by the lab in Ari 
Discussion
Because of the extent of her hepatic metastases, localized therapy such as radiofrequency ablation was not a valid option for this patient. She needed a more regional liver therapy, such as yttrium-90 radioembolization or chemoembolization. The patient tolerated the hepatic angiograms and SIR-Spheres radioembolization without any significant side effects. After radioembolization, radiation fatigue is common, lasting up to 1 month, and all patients will have a transient increase in their liver function studies. Posttreatment contrast-enhanced CT scans are often misread as progression of disease due to tumor edema. PET scans and tumor markers are more reflective of residual disease. It may take the CT up to 1 year to mirror the PET finding. A scan from February 2, 2004, shows stable disease; S.M. is thus radiographically and clinically stable 13 months after her SIR-Spheres injection. As exemplified by this patient, SIR-Spheres radioembolization may be useful in stabilizing hepatic metastases and should be used in conjunction with systemic therapies.
The comprehensive treatment plan developed for S.M. appears to have enabled a full hepatic remission. Hepatic metastases are notoriously stubborn and resistant to therapy and are usually progressive. Two common therapeutic approaches to hepatic disease are resection and cytotoxic therapy. S.M. was not a A B candidate for resection as she presented with diffuse hepatic metastatic lesions. Although there was some initial decrease in one main lesion with a cytotoxiccontaining integrative therapy and a concomitant decrease in the CEA level, ultimately there was an increase. Furthermore, when treated with cytotoxics, metastatic lesions can develop drug resistance. Yttrium-90 radioembolization was the preferred treatment for S.M.; its use enabled the local delivery and durable activity of radioactive spheres, thus sparing other tissues from radiation exposure. In addition, the hepatic disease was the major, potentially lethal focus of the disease at the time of SIR-Spheres administration, another reason for suggesting local treatment. S.M. fared well clinically during her courses of yttrium-90. This may have been in part due to the nontoxic treatments she was undergoing such as the intravenous vitamin C and oral supplementation; her postyttirum-90 recovery was abbreviated.
Conclusion
A broad and comprehensive understanding of the biology of S.M.'s cancer allowed construction of a regimen that integrated supplements and diet change with an innovative conventional approach. As a result, S.M. was able to tolerate without significant side effects a treatment that improved the quality and perhaps the quantity of her life.
